Autoimmune disease in women

Last updated

Autoimmunity refers to a pathological immune response of the body's immune system against itself. Autoimmune disease is widely recognized to be significantly more common in women than in men, and often presents differently between the sexes. [1] [2] [3] The reasons for these disparities are still under investigation, but may in part involve the presence of an additional X chromosome in women [3] (given that several genes on the X chromosome are associated with immune system development), as well as the higher presence of female sex hormones such as estrogen (which increases immune system response). [3] The risk, incidence, and character of autoimmune disease in women may also be associated with female-specific physiological changes, such as hormonal shifts during menses, pregnancy, and menopause. [4]

Contents

Common autoimmune symptoms experienced by both sexes include rashes, fevers, fatigue, and joint pain. Symptoms which are specific to women include irregular menses, pelvic pain, or vaginal dryness, depending on the given disease. Some diseases such as Graves' disease, rheumatoid arthritis, and multiple sclerosis [5] [6] may improve during pregnancy, whereas others such as lupus may worsen. [5] [6] [7]

Currently it is not possible to cure autoimmune disease, but many treatments are available. Treatment of autoimmune disease can be broadly classified into anti-inflammatory, immunosuppressive, and palliative – i.e., correcting a functional disturbance related to the condition. [8] Some medications used to treat autoimmune diseases might not be safe to use during pregnancy. [2] [8]

Common diseases

Autoimmune Disease Cases by Sex
DiseaseRatio of female:male cases
Addison's disease 1.5:1 [9]
Ankylosing spondylitis 1:3 [10] – 1:4 [11]
anti-GBM disease (Goodpasture syndrome) 1:2 – 1:9 [12]
Antiphospholipid syndrome 3.5:1 [13]
Autoimmune hepatitis 3:1 [14]
Behçet's disease 1:5 – 2:1 [15]
Celiac disease 1.5:1 – 2:1 [16]
Crohn's disease 1:1 [17] [18] (though F>M after age 25)
Dermatomyositis 2:1 – 3:1 [19]
Diabetes type 1 1:1.8 [20]
Giant cell arteritis 3:1 [21] – 4:1 [22]
Graves' disease 5:1 [23] [24]
Hashimoto's thyroiditis 4:1 – 9:1 [25]
Multiple sclerosis 2:1 – 3:1 [26]
Myelin Oligodendrocyte Glycoprotein

Antibody-Associated Disease (MOGAD)

1:1 [27]
Myasthenia gravis 3:1 [28] (below 40 years of age)
Neuromyelitis Optica (NMOSD) 9:1 [29]
Pemphigus vulgaris 2:1 [30]
Polymyositis 2:1 [31]
Primary biliary cholangitis 9:1 [32]
Primary sclerosing cholangitis 1:2 [33]
Rheumatoid arthritis 2:1 [34]
Sjögren syndrome 9:1 [35]
Systemic lupus erythematosus 9:1 [36]
Systemic sclerosis (scleroderma) 3:1 – 9:1 [37]
Takayasu's arteritis 9:1 [38]
Ulcerative colitis 1:1 [39] (though M>F after age 45)

There are over 100 autoimmune conditions described, of which the majority are more prevalent in women than in men. [8] Approximately 80% of all patients with autoimmune disease are women. [8]

Autoimmune diseases which overwhelmingly affect women include those which affect the thyroid gland (Hashimoto's thyroiditis, Graves' disease), rheumatic diseases (systemic lupus erythematosus, rheumatoid arthritis, scleroderma, and Sjögren syndrome), hepatobiliary diseases (primary biliary cholangitis, autoimmune hepatitis), [40] and neurological diseases (myasthenia gravis, neuromyelitis optica spectrum disorders (NMOSD), and multiple sclerosis). For men who may develop these conditions, epidemiological and symptomological differences may still exist. For example, when multiple sclerosis and rheumatoid arthritis do occur in men, they tend to develop later in life for men (around age 30–40) than for women, when incidence rises after puberty. [3]

Some autoimmune diseases affect both sexes at roughly equal rates, or have only a slight female predominance. [40] These conditions include inflammatory bowel disease (ulcerative colitis, Crohn's disease), immune thrombocytopenic purpura (ITP), and MOG antibody disease, among others. Although the lifetime incidence of these diseases may be similar, they may still exist a difference in disease onset, course, complications, and prognosis which vary based on sex. For example, men are more likely to develop Crohn's disease in the upper GI tract compared to women. [41] Males and females are equally as likely to be affected by Crohn's disease until around age 25, when women become overrepresented as Crohn's disease patients. [39] Women and men are equally likely to develop ulcerative colitis until age 45, after which this shifts to a significant male predominance. [39]

Very few autoimmune diseases are thought to be more common in men than in women. Examples of these may include ankylosing spondylitis, primary sclerosing cholangitis, type 1 diabetes, and certain vasculitides including anti-GBM disease (Goodpasture syndrome) and Behçet's disease (though whether this represents an autoimmune disease vs autoinflammatory disease remains unclear.) On closer inspection, some diseases initially thought to be overrepresented in men have trended towards sex neutrality over time. For example, early studies of ankylosing spondylitis reported a ratio of 10:1 male to female patients, but more recent reports have indicated this is closer to 3:1. [10] This may reflect a true increased incidence in women over time, or may be due to improvements in diagnostic testing.

Additionally, sex ratios of affected patients can vary widely between geographic regions. For instance, Crohn's disease is slightly more common in women in Western countries, whereas it is slightly more common in men in Asian countries. [41] Behçet's disease is more common in males in regions along the historic Silk Road, but is more common in women in the United States. [15] This suggests that the risks of developing autoimmune disease are multifactorial, and may vary based on race and environment as well as sex.

Signs and symptoms

Autoimmune diseases can result in systemic or localized symptoms, depending on the given disease. [8] Typical systemic symptoms include fevers, fatigue, muscle aches, joint pain, and rashes; these can be seen in diseases such as lupus or rheumatoid arthritis. Other autoimmune diseases have localized effects on specific organ or tissue types. For instance, alopecia areata presents with patchy baldness due to autoimmune destruction of hair follicles, whereas multiple sclerosis presents with neurological symptoms due to autoimmune demyelination of the central nervous system.

Both systemic and localized disease can present with symptoms which are exclusive to women. Women with Sjögren syndrome (an autoimmune disease characterized by destruction and inflammation of the salivary and lacrimal glands) are 2–3 times more likely to report vaginal dryness than other postmenopausal women. [42]

Causes

The causes of autoimmunity are still the subject of extensive research, and include genetic as well as environmental factors. However, the clear overrepresentation of women as persons with autoimmune disease suggests that sex-specific factors are highly instrumental in the development of these conditions. Posited reasons for this disparity include the differential effects of sex hormones (especially estrogen) on immune response, X-chromosome inactivation, changes associated with pregnancy, and evolutionary pressures that affect the sexes differently. [6] Due to biological development, many of these elements are inextricably linked, and it can be difficult to isolate the individual effects of each factor.

X chromosome inactivation

Many genes involved in the immune response reside on the X chromosome, of which most women have two copies, whereas men typically only have one. During cell division in embryological development, one of the two X chromosomes is inactivated at random, in a process called lyonization. This ensures that the expression of X chromosome genes is randomly suppressed on one of the two copies in females in order to compensate for the extra copy of these genes. [43] Incomplete suppression of the extra copies of these genes may lead to overexpression of some genes involved in the immune response resulting in a more robust immune response and an increased risk of developing autoimmune diseases. [43]

Additional support for this hypothesis can be illustrated by the higher rates of autoimmune disease in men with Klinefelter syndrome (47,XXY). [44] Like women, males with Klinefelter syndrome also have two copies of the X chromosome, which may predispose them to increased risk of autoimmune disease through the same mechanism. [44] This risk is highest in autoimmune diseases which are female-predominant (e.g., Addison's disease, multiple sclerosis, Sjögren syndrome). [44] With the exception of Type 1 diabetes, which affects both sexes at roughly equal rates, Klinefelter syndrome was not correlated with increased risk of autoimmune diseases which occur in males with greater or equal frequency [44] (e.g., ankylosing spondylitis, psoriasis.)

Despite having only one copy of the X chromosome, women with Turner syndrome (45,XO) are still twice as likely as the general female population to develop autoimmune diseases. [45] Interestingly, the autoimmune diseases for which Turner syndrome patients are at greater risk include inflammatory bowel disease, type 1 diabetes, alopecia areata, and several other autoimmune disorders which tend to affect the sexes at roughly equal rates. This suggests that the development of autoimmune disease is not solely mediated by differential expression of genes on the X chromosome.

Sex hormones

Sex hormones are instrumental in nearly every aspect of human biology, including the development and response of the adaptive immune system. Sex hormones such as estrogen, progesterone, and testosterone are all present in healthy men and women, albeit at different levels. Estrogen and progesterone are considered primary female sex hormones, while testosterone is the primary male sex hormone. Broadly speaking, estrogen is understood to be immune-activating, while testosterone is considered to be immune-suppressing. The ideal immune system response must be alert enough to recognize and destroy foreign antigens, while also being selective enough to avoid attacking the self. There exists a necessary trade-off between immune system hyperactivity (autoimmunity) versus hypoactivity (immune deficiency). Since men and women have different levels of these sex hormones, they necessarily incur unequal risk for developing these conditions. Very broadly speaking, men are more predisposed to infectious disease, but are less likely to develop autoimmune disease. Women conversely are at higher risk for developing autoimmune disease, but are more protected from infectious disease than men. Women have a greater number of circulating antibodies than do men, [46] which has implications for their development of autoimmune disease, as well as their increased resistance to infectious disease.

Estrogen

Estrogen has significant effects on the response of the adaptive immune system. [47] Higher levels of estrogen are correlated with higher levels of circulating antibodies, which are responsible for mounting an immune response. [46] In addition to short-term changes, the immune system may also be influenced by longer-term changes, such as total lifetime exposure. The course of disease may also be related to hormonal fluctuations, especially those of puberty, pregnancy, and menopause.

Testosterone

The immunocompetence handicap hypothesis proposes that testosterone may have utility as a secondary sexual characteristic which signals fitness to prospective mates. [48] [49] As males have higher levels of testosterone, which suppresses immune system activity, signaling fitness in spite of this handicap is a demonstration of mate quality in spite of this handicap. Additional proof-of-concept can be demonstrated through testosterone supplementation. Men with Klinefelter syndrome (47,XXY) naturally make very little testosterone; androgen supplementation has been shown to decrease serum levels of all immunoglobulins in these men. [50]

Pregnancy

Pregnancy has both short- and long-term effects on the immune system, and these changes may persist even after the completion of pregnancy. These effects on the course of autoimmune diseases vary widely, and are dependent on the specific disease, as well as the individual patient. Conditions such as rheumatoid arthritis often improve over the course of pregnancy, especially in the second and third trimesters; however, women often relapse within three months of giving birth. [7] Other conditions, such as lupus, often become much worse over the course of pregnancy. [5] [7]

During pregnancy, the hormone estrogen spikes; additionally, hormonal fluctuations may continue long after childbirth. [51] These changes could trigger, improve or even worsen an autoimmune disease. In addition to estrogen, other hormones like progesterone and prolactin may trigger these illnesses. [46]

The mother's immune system tends to be suppressed during pregnancy, to prevent fetal rejection from foreign antibodies in the fetus. [51] As stated before, pregnancy causes an increase of estrogen in the female body. The increase of this hormone weakens the functioning of immune cells, thus debilitating the mother's immune system. [47] In addition, it is possible that fetal cells continue to circulate in the mother's body for years after childbirth, making it a possible trigger for autoimmune disease. [52]

Diagnosis

Autoantibodies with commonly-associated autoimmune diseases
AutoantibodyCondition
ANA*("anti-nuclear antibody")Lupus
AHA ("anti-histone antibody")Drug-induced lupus
ds-DNA ("anti-double stranded DNA antibody")Systemic lupus erythematosus with renal involvement
SMA ("anti-smooth muscle antibody")Autoimmune Hepatitis
AMA ("anti-mitochondrial antibody")Primary Biliary Cirrhosis
ACA ("anti-centromere antibody")Scleroderma (CREST)
SS-A/Ro Ab ("anti-Sjögren syndrome A"/"anti-Ro" antibody)Sjögren syndrome
CCP ("anti-cyclic citrullinated peptide")Rheumatoid Arthritis
RF (rheumatoid factor)Rheumatoid Arthritis
Jo ("anti-Jo antibody")Polymyositis
anti-Scl-70 ("anti-topoisomerase I antibody")Systemic Scleroderma

Diagnosis of autoimmune disease is based upon clinical and laboratory evidence. [8] In order to diagnose autoimmune disease, typical symptoms of a given disorder must be present, along with laboratory evidence of autoantibodies. Autoantibodies develop throughout the course of autoimmune disease, as the immune system mistakenly forms specific antibodies to its own tissues, resulting in inflammation. The presence of autoantibodies alone is not sufficient for diagnosis, as autoantibodies may arise for a variety of other reasons, including malignancy, infection, or injury, and may be present even in persons who are completely healthy. [8] However, it is possible for persons to have detectable autoantibody levels prior to clinical development autoimmune disease; this state may be characterized as pre-autoimmunity. [8] Additionally, it is possible to display clinical signs of autoimmune disease before autoantibody levels are detectable. [8] Most autoantibody assays are more sensitive than they are specific; that is, a negative autoantibody test is better at excluding a given disease, than a positive autoantibody test is at diagnosing a disease.

Generally, autoantibody results are reported in the form of titers, with higher titers (e.g., 1:160) indicating greater autoantibody concentration than lower titers (e.g., 1:8). Different autoantibody assays will have different criteria for determining whether a given test is positive, negative, or indeterminate. Other laboratories ordered in the workup of autoimmune disease may include a white blood cell count (WBC), CRP (C-reactive protein), ESR (erythrocyte sedimentation rate), and C3/C4 (complement levels), among others.

Additional circumstantial evidence to indicate likely autoimmune disease include family history and clustering of autoimmune diseases within a given family, presence of HLA haplotypes associated with a given disease, sex bias, and proof-of-concept through response to immunosuppressive therapy. [8]

Treatment

Currently, it is not possible to fully cure any autoimmune disease. However, treatments exist which can improve the course of a given disease and/or result in long periods of remission. [8] Pharmacological treatment of autoimmune disease can be broadly classified into anti-inflammatory, immunosuppressive, and palliative – e.g., correcting a functional disturbance related to the condition. The overall goals of such treatment are to limit the severity of flare-ups of disease, as well as to limit the total number of flares – that is, to extend periods of disease remission.

Anti-inflammatory

Nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used to reduce inflammation associated with flares of autoimmune illness. NSAIDs work by inhibiting COX-1 and COX-2 enzymes, [53] which are responsible for generating prostaglandins which cause inflammation. They additionally may inhibit chemotaxis, stop neutrophil aggregation, and decrease levels of pro-inflammatory cytokines. [53] They are not considered immunosuppressive agents, as they do not directly target immune cells. Examples of NSAIDs include ibuprofen, naproxen, and diclofenac. These drugs are not recommended past the 20th week of pregnancy, as they may have adverse effects on development of the fetal circulatory system and kidneys. [53]

Corticosteroids

Corticosteroids also have both anti-inflammatory and immunosuppressive effects, [54] and are used widely in the treatment of autoimmune disease. They work through promoting the synthesis of multiple proteins such as lipocortin-1 and annexin A1, which stop the downstream production of prostaglandins and leukotrienes which promote inflammation. [54] Examples of corticosteroids used in autoimmune disease include prednisone and methylprednisolone. There are no robust randomized controlled studies in humans regarding the safety of corticosteroid use in pregnancy. [55] Corticosteroid use may be associated with cleft palate formation in the 1st trimester, [55] [56] but the data on this is limited. There is little evidence to suggest that material corticosteroid use is associated with early delivery, low birth weight, or preeclampsia. Prednisone and methylprednisolone have been classed as pregnancy category C, in that they should only be used in the maternal benefits outweigh potential risks to the fetus. [55]

Immunosuppressive

Optimal treatment of autoimmune disease addition to quelling the generalized inflammation which may occur with autoimmune disease, treatment is also focused on specifically targeting the adaptive immune system. The goal of direct immunosuppression is to treat flares as well as extend the period of remission between episodes. Immunosuppressive drugs are categorized into DMARDs (disease-modifying anti-rheumatic drugs), as well as[ clarification needed ]

DMARDs (Disease-Modifying Anti-Rheumatic Drugs)

DMARDs can be further classified into conventional-synthetic, targeted-synthetic, and biologic agents.

Palliative

Some autoimmune diseases with targeted effects on endocrine organs can result in an inability to produce hormones necessary to maintain normal physiology. Palliative treatment of autoimmune disease involves treating the secondary condition, by replacing vital hormones which are no longer being produced. Examples of this include the treatment of type-1 diabetes with exogenous insulin. Though this does not cure the primary autoimmune disease, it effectively treats the lack of hormone caused by it.

Non-pharmacological

Non-pharmacological treatments are effective in treating autoimmune disease and contribute to a sense of well-being. Women can:

Complementary

Some complementary treatments may be effective and include:

During pregnancy

Concerns about fertility and pregnancy are present in women with autoimmune diseases. Talking with a health care provider before becoming pregnant is recommended. They may suggest to wait until the disease is in remission or suggest a change in medication before becoming pregnant. There are endocrinologists that specialize in treating women with high-risk pregnancies. [2]

Some women with autoimmune diseases may have problems getting pregnant. This can happen for many reasons such as medication types or even disease types. [59] Tests can tell if fertility problems are caused by an autoimmune disease or an unrelated reason. Fertility treatments are able to help some women with autoimmune disease become pregnant. [2]

Changes in the severity of the disease seem to vary depending on the type of disease. There is an observable trend in pregnant women with rheumatoid arthritis, where the condition seems to improve during pregnancy. [7] Differently, expecting mothers with systemic lupus erythematosus (SLE) may be more likely to have worsened symptoms through pregnancy; however, this is difficult to predict. [7]

Medications have an influence on female fertility a well; furthermore, fertility has an impact on pregnancy. There are certain medications that can hinder women's ability to get pregnant, such as cyclophosphamide or corticosteroids. [59] For this reason, it may be extremely helpful for women with autoimmune diseases to seek treatment when conceiving.

Related Research Articles

<span class="mw-page-title-main">Sjögren syndrome</span> Autoimmune disease affecting the bodys moisture-producing glands

Sjögren syndrome or Sjögren's syndrome is a long-term autoimmune disease that affects the body's moisture-producing glands, and often seriously affects other organ systems, such as the lungs, kidneys, and nervous system.

<span class="mw-page-title-main">Hypothyroidism</span> Endocrine disease

Hypothyroidism is a disorder of the endocrine system in which the thyroid gland does not produce enough thyroid hormones. It can cause a number of symptoms, such as poor ability to tolerate cold, a feeling of tiredness, constipation, slow heart rate, depression, and weight gain. Occasionally there may be swelling of the front part of the neck due to goitre. Untreated cases of hypothyroidism during pregnancy can lead to delays in growth and intellectual development in the baby or congenital iodine deficiency syndrome.

<span class="mw-page-title-main">Autoimmunity</span> Immune response against an organisms own healthy cells

In immunology, autoimmunity is the system of immune responses of an organism against its own healthy cells, tissues and other normal body constituents. Any disease resulting from this type of immune response is termed an "autoimmune disease". Prominent examples include celiac disease, diabetes mellitus type 1, Henoch–Schönlein purpura (HSP), systemic lupus erythematosus (SLE), Sjögren syndrome, eosinophilic granulomatosis with polyangiitis, Hashimoto's thyroiditis, Graves' disease, idiopathic thrombocytopenic purpura, Addison's disease, rheumatoid arthritis (RA), ankylosing spondylitis, polymyositis (PM), dermatomyositis (DM), and multiple sclerosis (MS). Autoimmune diseases are very often treated with steroids.

<span class="mw-page-title-main">Antinuclear antibody</span> Autoantibody that binds to contents of the cell nucleus

Antinuclear antibodies are autoantibodies that bind to contents of the cell nucleus. In normal individuals, the immune system produces antibodies to foreign proteins (antigens) but not to human proteins (autoantigens). In some cases, antibodies to human antigens are produced.

<span class="mw-page-title-main">Hashimoto's thyroiditis</span> Autoimmune disease

Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis and Hashimoto's disease, is an autoimmune disease in which the thyroid gland is gradually destroyed. A slightly broader term is autoimmune thyroiditis, identical other than that it is also used to describe a similar condition without a goitre.

An autoantibody is an antibody produced by the immune system that is directed against one or more of the individual's own proteins. Many autoimmune diseases are associated with such antibodies.

Mixed connective tissue disease, commonly abbreviated as MCTD, is an autoimmune disease characterized by the presence of elevated blood levels of a specific autoantibody, now called anti-U1 ribonucleoprotein (RNP) together with a mix of symptoms of systemic lupus erythematosus (SLE), scleroderma, and polymyositis. The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., and the term was introduced by Leroy in 1980.

Palindromic rheumatism (PR) is a syndrome characterised by recurrent, self-resolving inflammatory attacks in and around the joints, and consists of arthritis or periarticular soft tissue inflammation. The course is often acute onset, with sudden and rapidly developing attacks or flares. There is pain, redness, swelling, and disability of one or multiple joints. The interval between recurrent palindromic attacks and the length of an attack is extremely variable from few hours to days. Attacks may become more frequent with time but there is no joint damage after attacks. It is thought to be an autoimmune disease, possibly an abortive form of rheumatoid arthritis.

Scleromyositis, is an autoimmune disease. People with scleromyositis have symptoms of both systemic scleroderma and either polymyositis or dermatomyositis, and is therefore considered an overlap syndrome. Although it is a rare disease, it is one of the more common overlap syndromes seen in scleroderma patients, together with MCTD and Antisynthetase syndrome. Autoantibodies often found in these patients are the anti-PM/Scl (anti-exosome) antibodies.

<span class="mw-page-title-main">Autoimmune disease</span> Disorders of adaptive immune system

An autoimmune disease is a condition that results from an anomalous response of the adaptive immune system, wherein it mistakenly targets and attacks healthy, functioning parts of the body as if they were foreign organisms. It is estimated that there are more than 80 recognized autoimmune diseases, with recent scientific evidence suggesting the existence of potentially more than 100 distinct conditions. Nearly any body part can be involved.

<span class="mw-page-title-main">Lupus</span> Human autoimmune disease

Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.

<span class="mw-page-title-main">Scleroderma</span> Group of autoimmune diseases resulting in abnormal growth of connective tissue

Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, muscles, and internal organs. The disease can be either localized to the skin or involve other organs, as well. Symptoms may include areas of thickened skin, stiffness, feeling tired, and poor blood flow to the fingers or toes with cold exposure. One form of the condition, known as CREST syndrome, classically results in calcium deposits, Raynaud's syndrome, esophageal problems, thickening of the skin of the fingers and toes, and areas of small, dilated blood vessels.

Cryoglobulinemic vasculitis is a form of inflammation affecting the blood vessels caused by the deposition of abnormal proteins called cryoglobulins. These immunoglobulin proteins are soluble at normal body temperatures, but become insoluble below 37 °C (98.6 °F) and subsequently may aggregate within smaller blood vessels. Inflammation within these obstructed blood vessels is due to the deposition of complement proteins which activate inflammatory pathways.

The Undifferentiated connective tissue disease (UCTD) is a disease in which the connective tissues are targeted by the immune system. It is a serological and clinical manifestation of an autoimmune disease. When there is proof of an autoimmune disease, it will be diagnosed as UCTD if the disease doesn't answer to any criterion of specific autoimmune disease. Such as systemic lupus erythematosus (SLE), la scleroderma, mixed connective tissue disease, Sjögren syndrome, systemic sclerosis, polymyositis, dermatomyositis, or the rheumatoid arthritis. This is also the case of major rheumatic diseases whose early phase was defined by LeRoy et al. in 1980 as undifferentiated connective tissue disease. The latent Lupus and the incomplete lupus are alternative terms used to describe this condition.

<span class="mw-page-title-main">Anti-SSA/Ro autoantibodies</span> Type of anti-nuclear autoantibodies

Anti-SSA autoantibodies are a type of anti-nuclear autoantibodies that are associated with many autoimmune diseases, such as systemic lupus erythematosus (SLE), SS/SLE overlap syndrome, subacute cutaneous lupus erythematosus (SCLE), neonatal lupus and primary biliary cirrhosis. They are often present in Sjögren's syndrome (SS). Additionally, Anti-Ro/SSA can be found in other autoimmune diseases such as systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), rheumatoid arthritis (RA), and mixed connective tissue disease (MCTD), and are also associated with heart arrhythmia.

<span class="mw-page-title-main">Antisynthetase syndrome</span> Medical condition

Antisynthetase syndrome (ASS) is a multisystematic autoimmune disease associated with inflammatory myositis, interstitial lung disease, and antibodies directed against various synthetases of aminoacyl-transfer RNA. Other common symptoms include mechanic's hands, Raynaud's phenomenon, arthritis, and fever.

<span class="mw-page-title-main">LRBA deficiency</span> Medical condition

LRBA deficiency is a rare genetic disorder of the immune system. This disorder is caused by a mutation in the gene LRBA. LRBA stands for “lipopolysaccharide (LPS)-responsive and beige-like anchor protein”. This condition is characterized by autoimmunity, lymphoproliferation, and immune deficiency. It was first described by Gabriela Lopez-Herrera from University College London in 2012. Investigators in the laboratory of Dr. Michael Lenardo at National Institute of Allergy and Infectious Diseases, the National Institutes of Health and Dr. Michael Jordan at Cincinnati Children’s Hospital Medical Center later described this condition and therapy in 2015.

Rhonda Renee Voskuhl is an American physician, research scientist, and professor. She is a member of the Brain Research Institute (BRI) at the David Geffen School of Medicine at UCLA and is the director of its Multiple Sclerosis Program. Voskuhl has published numerous scientific articles in academic journals and has served in the role of principal investigator for several treatment trials investigating potential treatments for multiple sclerosis (MS).

<span class="mw-page-title-main">Robert G. Lahita</span> American physician

Robert George Lahita is an American physician, internist and rheumatologist, best known for his research into systemic lupus erythematosus. and other autoimmune diseases. He is the author of more than 16 books and 150 scientific publications in the field of autoimmunity and immuno-endocrinology and a media consultant on health-related issues. He currently serves as Director of the Institute of Autoimmune and Rheumatic Diseases at St. Joseph's Healthcare System, specializing in autoimmunity, rheumatology, and treatment of diseases of joints, muscle, bones and tendons including arthritis, back pain, muscle strains, common athletic injuries and collagen diseases.

Epigenetics of autoimmune disorders is the role that epigenetics play in autoimmune diseases. Autoimmune disorders are a diverse class of diseases that share a common origin. These diseases originate when the immune system becomes dysregulated and mistakenly attacks healthy tissue rather than foreign invaders. These diseases are classified as either local or systemic based upon whether they affect a single body system or if they cause systemic damage.

References

  1. ↑ Kronzer VL, Bridges SL, Davis JM (March 2021). "Why women have more autoimmune diseases than men: An evolutionary perspective". Evolutionary Applications. 14 (3): 629–633. Bibcode:2021EvApp..14..629K. doi:10.1111/eva.13167. PMC   7980266 . PMID   33767739.
  2. 1 2 3 4 5 6 7 8 9 "Autoimmune Diseases". Office on Women's Health, U.S. Department of Health and Human Services. 1 February 2017. Retrieved 20 July 2017.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  3. 1 2 3 4 Voskuhl R (January 2011). "Sex differences in autoimmune diseases". Biology of Sex Differences. 2 (1): 1. doi: 10.1186/2042-6410-2-1 . PMC   3022636 . PMID   21208397.
  4. ↑ Angum F, Khan T, Kaler J, Siddiqui L, Hussain A (May 2020). "The Prevalence of Autoimmune Disorders in Women: A Narrative Review". Cureus. 12 (5): e8094. doi: 10.7759/cureus.8094 . PMC   7292717 . PMID   32542149.
  5. 1 2 3 Anaya JM, Shoenfeld Y, Rojas-Villarraga A, Levy RA, Cervera R (2013). Autoimmunity: From Bench to Bedside (1st ed.). Center for Autoimmune Diseases Research, School of Medicine and Health Sciences, El Rosario University. pp. 257–265. ISBN   978-958-738-376-8.
  6. 1 2 3 Moyer MW (September 2021). "Why Nearly 80 Percent of Autoimmune Sufferers Are Female". Scientific American. Retrieved 2023-11-14.
  7. 1 2 3 4 5 Adams Waldorf KM, Nelson JL (2008). "Autoimmune disease during pregnancy and the microchimerism legacy of pregnancy". Immunological Investigations. 37 (5): 631–644. doi:10.1080/08820130802205886. PMC   2709983 . PMID   18716941.
  8. 1 2 3 4 5 6 7 8 9 10 11 Pisetsky DS (October 11, 2023). Schur PH, Rigby WF, Case SM (eds.). "Overview of autoimmunity". UpToDate. Retrieved November 14, 2023.
  9. ↑ Chabre O, Goichot B, Zenaty D, Bertherat J (December 2017). "Group 1. Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality". Annales d'Endocrinologie. 78 (6): 490–494. doi:10.1016/j.ando.2017.10.010. PMID   29174931.
  10. 1 2 Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE (May 2018). "Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky". Current Rheumatology Reports. 20 (6): 35. doi:10.1007/s11926-018-0744-2. PMC   5949138 . PMID   29754330.
  11. ↑ van Tubergen A. Sieper J, Seo P (eds.). "Clinical manifestations of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults". UpToDate. Retrieved November 20, 2023.
  12. ↑ Raval P (2015). "Goodpasture's Syndrome☆". Reference Module in Biomedical Sciences. Elsevier. doi:10.1016/b978-0-12-801238-3.05046-7. ISBN   978-0-12-801238-3 . Retrieved 2023-11-21.
  13. ↑ Truglia S, Capozzi A, Mancuso S, Manganelli V, Rapino L, Riitano G, et al. (2022-07-04). "Relationship Between Gender Differences and Clinical Outcome in Patients With the Antiphospholipid Syndrome". Frontiers in Immunology. 13. doi: 10.3389/fimmu.2022.932181 . ISSN   1664-3224. PMC   9289158 . PMID   35860235.
  14. ↑ Grønbaek L, Otete H, Ban L, Crooks C, Card T, Jepsen P, West J (July 2020). "Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. A population-based cohort study" (PDF). Liver International. 40 (7): 1634–1644. doi:10.1111/liv.14480. PMID   32304617. S2CID   215819311.
  15. 1 2 Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, et al. (January 2017). "Behcet's disease: epidemiology, clinical manifestations, and diagnosis". Expert Review of Clinical Immunology. 13 (1): 57–65. doi:10.1080/1744666X.2016.1205486. PMID   27351485. S2CID   24855570.
  16. ↑ Fasano A, Catassi C (December 2012). "Clinical practice. Celiac disease". The New England Journal of Medicine. 367 (25): 2419–2426. doi:10.1056/NEJMcp1113994. PMID   23252527.
  17. ↑ Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA (May 2001). "Gender-related differences in the clinical course of Crohn's disease". The American Journal of Gastroenterology. 96 (5): 1541–1546. doi:10.1111/j.1572-0241.2001.03755.x. PMID   11374696. S2CID   13058668.
  18. ↑ Loftus EV, Schoenfeld P, Sandborn WJ (January 2002). "The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review". Alimentary Pharmacology & Therapeutics. 16 (1): 51–60. doi:10.1046/j.1365-2036.2002.01140.x. hdl: 2027.42/72031 . PMID   11856078. S2CID   9792673.
  19. ↑ Bendewald MJ, Wetter DA, Li X, Davis MD (January 2010). "Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota". Archives of Dermatology. 146 (1): 26–30. doi:10.1001/archdermatol.2009.328. PMC   2886726 . PMID   20083689.
  20. ↑ Tatti P, Pavandeep S (June 2022). "Gender Difference in Type 1 Diabetes: An Underevaluated Dimension of the Disease". Diabetology. 3 (2): 364–368. doi: 10.3390/diabetology3020027 . ISSN   2673-4540.
  21. ↑ Sharma A, Mohammad AJ, Turesson C (October 2020). "Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review". Seminars in Arthritis and Rheumatism. 50 (5): 1040–1048. doi: 10.1016/j.semarthrit.2020.07.005 . PMID   32911281. S2CID   221619856.
  22. ↑ Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. (March 2011). "The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases". Arthritis and Rheumatism. 63 (3): 633–639. doi:10.1002/art.30155. PMC   3078757 . PMID   21360492.
  23. ↑ Burch HB, Cooper DS (December 2015). "Management of Graves Disease: A Review". JAMA. 314 (23): 2544–2554. doi:10.1001/jama.2015.16535. PMID   26670972.
  24. ↑ Hemminki K, Li X, Sundquist J, Sundquist K (May 2010). "The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution". Journal of Autoimmunity. 34 (3): J307–J313. doi:10.1016/j.jaut.2009.11.019. PMID   20056533.
  25. ↑ Ragusa F, Fallahi P, Elia G, Gonnella D, Paparo SR, Giusti C, et al. (December 2019). "Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy". Best Practice & Research. Clinical Endocrinology & Metabolism. Autoimmune endocrine disorders: Part I. 33 (6): 101367. doi:10.1016/j.beem.2019.101367. PMID   31812326. S2CID   208955243.
  26. ↑ Golden LC, Voskuhl R (January 2017). "The importance of studying sex differences in disease: The example of multiple sclerosis". Journal of Neuroscience Research. 95 (1–2): 633–643. doi:10.1002/jnr.23955. PMC   5825192 . PMID   27870415.
  27. ↑ Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, Lopez-Chiriboga AS, Pittock SJ, Flanagan EP (2022). "Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management". Frontiers in Neurology. 13: 885218. doi: 10.3389/fneur.2022.885218 . PMC   9247462 . PMID   35785363.
  28. ↑ Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J (2012). "Myasthenia gravis: a review". Autoimmune Diseases. 2012: 874680. doi: 10.1155/2012/874680 . PMC   3501798 . PMID   23193443.
  29. ↑ Nytrova P, Dolezal O (2022). "Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: How it influences clinical course, MRI parameters and prognosis". Frontiers in Immunology. 13: 933415. doi: 10.3389/fimmu.2022.933415 . PMC   9396644 . PMID   36016923.
  30. ↑ Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J (July 2008). "Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study". BMJ. 337 (7662): a180. doi:10.1136/bmj.a180. PMC   2483869 . PMID   18614511.
  31. ↑ Hammer GD, McPhee SJ, eds. (2019). Pathophysiology of disease: an introduction to clinical medicine. A LANGE medical book (Eighth ed.). New York: McGraw-Hill Education. ISBN   978-1-260-02650-4.
  32. ↑ Kaplan MM, Gershwin ME (September 2005). "Primary biliary cirrhosis". The New England Journal of Medicine. 353 (12): 1261–1273. doi:10.1056/NEJMra043898. PMID   16177252.
  33. ↑ Hirschfield GM, Karlsen TH, Lindor KD, Adams DH (November 2013). "Primary sclerosing cholangitis". The Lancet. 382 (9904): 1587–1599. doi:10.1016/S0140-6736(13)60096-3. PMID   23810223. S2CID   13423425.
  34. ↑ Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, et al. (October 2022). "Global epidemiology of rheumatoid arthritis". Nature Reviews. Rheumatology. 18 (10): 591–602. doi:10.1038/s41584-022-00827-y. PMID   36068354. S2CID   252081294.
  35. ↑ Mariette X, Criswell LA (March 2018). Solomon CG (ed.). "Primary Sjögren's Syndrome". The New England Journal of Medicine. 378 (10): 931–939. doi:10.1056/NEJMcp1702514. PMID   29514034. S2CID   3818757.
  36. ↑ Lisnevskaia L, Murphy G, Isenberg D (November 2014). "Systemic lupus erythematosus". Lancet. 384 (9957): 1878–1888. doi:10.1016/S0140-6736(14)60128-8. PMID   24881804. S2CID   28905456.
  37. ↑ Hughes M, Pauling JD, Armstrong-James L, Denton CP, Galdas P, Flurey C (April 2020). "Gender-related differences in systemic sclerosis". Autoimmunity Reviews. 19 (4): 102494. doi:10.1016/j.autrev.2020.102494. PMID   32062031. S2CID   211134815.
  38. ↑ Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM (August 2020). "Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences". Current Rheumatology Reports. 22 (10): 68. doi:10.1007/s11926-020-00948-x. PMC   9112376 . PMID   32845392.
  39. 1 2 3 Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, et al. (October 2018). "Sex-Based Differences in Incidence of Inflammatory Bowel Diseases—Pooled Analysis of Population-Based Studies From Western Countries". Gastroenterology. 155 (4): 1079–1089.e3. doi: 10.1053/j.gastro.2018.06.043 . PMID   29958857. S2CID   49618158.
  40. 1 2 Lockshin MD (2005). "Sex Differences in Autoimmune Disease". In Lockshin M, Branch DW, Asherson RA (eds.). Reproductive and Hormonal Aspects of Systemic Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases Vol. 4. Vol. 4. Elsevier. pp. 3–10. doi:10.1016/s1571-5078(05)04002-x. ISBN   978-0-444-51801-9.
  41. 1 2 Lungaro L, Costanzini A, Manza F, Barbalinardo M, Gentili D, Guarino M, et al. (2023-01-17). "Impact of Female Gender in Inflammatory Bowel Diseases: A Narrative Review". Journal of Personalized Medicine. 13 (2): 165. doi: 10.3390/jpm13020165 . ISSN   2075-4426. PMC   9958616 . PMID   36836400.
  42. ↑ "Gynecologic Problems". Johns Hopkins Sjögren’s Center. Retrieved 2023-11-30.
  43. 1 2 Xing E, Billi AC, Gudjonsson JE (March 2022). "Sex Bias and Autoimmune Diseases". The Journal of Investigative Dermatology. 142 (3 Pt B): 857–866. doi: 10.1016/j.jid.2021.06.008 . PMID   34362556. S2CID   236946919.
  44. 1 2 3 4 Seminog OO, Seminog AB, Yeates D, Goldacre MJ (March 2015). "Associations between Klinefelter's syndrome and autoimmune diseases: English national record linkage studies". Autoimmunity. 48 (2): 125–128. doi:10.3109/08916934.2014.968918. ISSN   1607-842X. PMID   25295757. S2CID   1533562.
  45. ↑ De Sanctis V, Khater D (2019-09-06). "Autoimmune diseases in Turner syndrome: an overview". Acta Bio Medica: Atenei Parmensis. 90 (3): 341–344. doi:10.23750/abm.v90i3.8737. PMC   7233727 . PMID   31580326.
  46. 1 2 3 Kronzer VL, Bridges SL, Davis JM (March 2021). "Why women have more autoimmune diseases than men: An evolutionary perspective". Evolutionary Applications. 14 (3): 629–633. Bibcode:2021EvApp..14..629K. doi:10.1111/eva.13167. PMC   7980266 . PMID   33767739.
  47. 1 2 Moulton VR (2018). "Sex Hormones in Acquired Immunity and Autoimmune Disease". Frontiers in Immunology. 9: 2279. doi: 10.3389/fimmu.2018.02279 . PMC   6180207 . PMID   30337927.
  48. ↑ Folstad, Ivar; Karter, Andrew John (March 1992). "Parasites, Bright Males, and the Immunocompetence Handicap". The American Naturalist. 139 (3): 603–622. doi:10.1086/285346. ISSN   0003-0147. S2CID   85266542.
  49. ↑ Braude, Stanton; Tang-Martinez, Zuleyma; Taylor, George T. (May 1999). "Stress, testosterone, and the immunoredistribution hypothesis". Behavioral Ecology . 10 (3): 345–350. doi: 10.1093/beheco/10.3.345 . ISSN   1465-7279.
  50. ↑ Koçar, I H; Yesilova, Z; Özata, M; Turan, M; Sengül, A; Özdemir, I ç (2001-12-24). "The effect of testosterone replacement treatment on immunological features of patients with Klinefelter's syndrome". Clinical and Experimental Immunology. 121 (3): 448–452. doi:10.1046/j.1365-2249.2000.01329.x. ISSN   1365-2249. PMC   1905740 . PMID   10973715.
  51. 1 2 Angum F, Khan T, Kaler J, Siddiqui L, Hussain A (May 2020). "The Prevalence of Autoimmune Disorders in Women: A Narrative Review". Cureus. 12 (5): e8094. doi: 10.7759/cureus.8094 . PMC   7292717 . PMID   32542149.
  52. ↑ Turner L (May 1, 2019). "Women's Health". Better Nutrition. 81: 32–35.
  53. 1 2 3 PubChem. "Ibuprofen". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-12-01.
  54. 1 2 PubChem. "Prednisone". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-12-01.
  55. 1 2 3 "Prednisone Use During Pregnancy". Drugs.com. Retrieved 2023-12-01.
  56. ↑ Bandoli, Gretchen; Palmsten, Kristin; Forbess Smith, Chelsey J.; Chambers, Christina D. (August 2017). "A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes". Rheumatic Disease Clinics of North America. 43 (3): 489–502. doi:10.1016/j.rdc.2017.04.013. PMC   5604866 . PMID   28711148.
  57. 1 2 Konijeti GG, Kim N, Lewis JD, Groven S, Chandrasekaran A, Grandhe S, et al. (November 2017). "Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease". Inflammatory Bowel Diseases. 23 (11): 2054–2060. doi:10.1097/MIB.0000000000001221. PMC   5647120 . PMID   28858071.
  58. ↑ Yi YS (2018). "Complementary and Alternative Therapy of Rare Inflammatory/Autoimmune Diseases". Evidence-Based Complementary and Alternative Medicine. 2018: 2140521. doi: 10.1155/2018/2140521 . PMC   5863355 . PMID   29707030.
  59. 1 2 Khizroeva J, Nalli C, Bitsadze V, Lojacono A, Zatti S, Andreoli L, et al. (December 2019). "Infertility in women with systemic autoimmune diseases". Best Practice & Research. Clinical Endocrinology & Metabolism. Autoimmune endocrine disorders: Part I. 33 (6): 101369. doi:10.1016/j.beem.2019.101369. PMID   31837981. S2CID   209384051.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.